Immunome Desmoid Tumor Drug Application Validated in Europe

09:36 AM EDT, 10/30/2026 (MT Newswires) -- Immunome (IMNM) said Friday the European Medicines Agency validated its marketing application for varegacestat, an oral treatment for adults with desmoid tumors, and the regulator will now begin its review. The drug reduced the risk of disease progression or death by 84% in a phase 3 trial versus placebo, with 56% of treated patients responding compared with 9% on placebo, meeting its primary and secondary endpoints, the company said. Common side effects were diarrhea in 82% of patients, fatigue in 44% and rash in 43%; 95% were mild or moderate, Immunome said. The US Food and Drug Administration also accepted a US application for the drug and set a decision date of April 28, 2027, it said. Shares of the company were down 1.3% in Friday premarket activity. Price: 18.38, Change: +0.09, Percent Change: +0.46